HC Wainwright set a $20.00 price target on Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) in a research report released on Tuesday. The brokerage currently has a buy rating on the stock.

RNN has been the topic of a number of other research reports. Zacks Investment Research raised shares of Rexahn Pharmaceuticals from a hold rating to a buy rating and set a $1.75 price target on the stock in a research report on Friday, August 10th. B. Riley set a $8.00 price target on shares of Rexahn Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 13th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $10.69.

Shares of Rexahn Pharmaceuticals stock opened at $1.82 on Tuesday. Rexahn Pharmaceuticals has a twelve month low of $1.23 and a twelve month high of $3.19.

Rexahn Pharmaceuticals (NYSEAMERICAN:RNN) last issued its quarterly earnings results on Monday, August 6th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.03.

An institutional investor recently raised its position in Rexahn Pharmaceuticals stock. Northern Trust Corp raised its position in shares of Rexahn Pharmaceuticals, Inc. (NYSEAMERICAN:RNN) by 61.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 77,213 shares of the company’s stock after acquiring an additional 29,354 shares during the quarter. Northern Trust Corp owned about 0.24% of Rexahn Pharmaceuticals worth $117,000 as of its most recent SEC filing.

Rexahn Pharmaceuticals Company Profile

Rexahn Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage drug candidates include RX-3117, which is in Phase II a clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase II a clinical study to treat patients with metastatic triple negative breast cancer.

See Also: How to Profit and Limit Losses With Stop Orders

Receive News & Ratings for Rexahn Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.